Dualitas Therapeutics vs Olema Oncology
Dualitas Therapeutics
Pioneering the Future of Bispecific Antibody Therapies
21 employees · est. 2023
Olema Oncology is the older company (2023 vs 2007); Olema Oncology is the larger of the two.
Side-by-Side Comparison
| Metric | Dualitas Therapeutics | Olema Oncology |
|---|---|---|
| Founded | ||
| Founded | 2023 | 2007 older |
| Headquarters | ||
| Headquarters | Not tracked yet | San Francisco, United States |
| Employees | ||
| Employees | 21 | 164 larger |
| Industry | ||
| Industry | Biotechnology | Biopharma, Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Series A | Post-IPO Equity |
| Total Funding | ||
| Total Funding | $65.00M | $325.05M |
| Funding Rounds | ||
| Funding Rounds | 1 | 5 |
| Services | ||
| Services | Development of bispecific antibodies, DualScreen Bispecific Discovery, Proximity Engager Mechanism, IND-enabling studies | Not tracked yet |
| Target Customers | ||
| Target Customers | Pharmaceutical Companies, Biotech Firms, Healthcare Providers Specializing in Autoimmune and Inflammatory Diseases, Research Institutions | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Bispecific Antibody TherapiesImmune DiseasesInflammatory DiseasesDualScreen Discovery EngineCell Surface Proximity EngagersPreclinical Evidence +8 | Biopharmaceutical CompanyTargeted TherapiesWomen's CancersOP-1250Estrogen Receptor AntagonistBreast Cancer Treatment +8 |
| Website | ||
| Website | dualitastx.com | olema.com |
About Dualitas Therapeutics
Dualitas Therapeutics, founded in 2023, is at the forefront of biotechnology innovation, with a focus on bispecific antibody therapies. The company is driven by its proprietary DualScreen™ discovery engine and aims to address unmet patient needs in immune and inflammatory (I&I) diseases through a pr...
About Olema Oncology
Olema Oncology is a biopharmaceutical company that focuses on developing innovative targeted therapies for women's cancers. Their lead program, OP-1250, is a potential best-in-class complete estrogen receptor antagonist (CERAN) designed to treat estrogen receptor-positive (ER+), human epidermal grow...
Also comparing in this category
We will tell you when either one moves
BounceWatch watches Dualitas Therapeutics and Olema Oncology for new funding, fast hiring, new executives and a change of software vendor. When one happens, it is in your next e-mail.
Get notified when Dualitas Therapeutics or Olema Oncology moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Frequently Asked Questions
Compare Dualitas Therapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Dualitas Therapeutics on 9 Jun 2026, and Olema Oncology on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
